Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey

被引：0

作者：

Demirci, Umut ^{[1
]}

Gokmen, Erhan ^{[2
]}

Eralp, Yesim ^{[3
]}

Gunduz, Seyda ^{[4
]}

Goksu, Sema Sezgin ^{[5
]}

Korkmaz, Taner ^{[6
]}

Kostek, Osman ^{[7
]}

Turhal, Serdar ^{[8
]}

Paydas, Semra ^{[9
]}

Topcu, Sevgi ^{[10
]}

Cakar, Burcu ^{[2
]}

Karabulut, Bulent ^{[2
]}

Tanriverdi, Ozgur ^{[11
]}

Karaca, Burcak ^{[2
]}

Deniz, Gulhan Ipek ^{[12
]}

Alan, Ozkan ^{[13
]}

Turkoz, Fatma Paksoy ^{[14
]}

Basaran, Gul ^{[15
]}

机构：

[1] Dr AY Ankara Oncol Hosp, Dept Med Oncol, Ankara, Turkey

[2] Ege Univ, Dept Med Oncol, Izmir, Turkey

[3] Florence Nightingale Hosp, Dept Med Oncol, Istanbul, Turkey

[4] Mem Antalya Hosp, Dept Med Oncol, Antalya, Turkey

[5] Akdeniz Univ, Dept Med Oncol, Antalya, Turkey

[6] Acibadem Mehmet Ali Aydinlar Univ, Dept Med Oncol, Istanbul, Turkey

[7] Trakya Univ, Dept Med Oncol, Edirne, Turkey

[8] Anadolu Med Ctr, Dept Med Oncol, Kocaeli, Turkey

[9] Cukurova Univ, Dept Med Oncol, Adana, Turkey

[10] Ege Univ, Dept Med Oncol, Izmir, Turkey

[11] Mugla Sitki Kocman Univ, Dept Med Oncol, Mugla, Turkey

[12] Istanbul Univ, Cerrahpasa Med Fac, Dept Med Oncol, Istanbul, Turkey

[13] Tekirdag State Hosp, Dept Med Oncol, Edirne, Turkey

[14] Med Pk Goztepe Hosp, Dept Med Oncol, Istanbul, Turkey

[15] Acibadem Mehmet Ali Aydinlar Univ, Dept Med Oncol, Istanbul, Turkey

来源：

CANCER RESEARCH | 2020年 / 80卷 / 04期

关键词：

D O I：

10.1158/1538-7445.SABCS19-P5-11-19

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P5-11-19

引用

页数：3

共 50 条

[11] FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Shah, Anand
Bloomquist, Erik
Tang, Shenghui
Fu, Wentao
Bi, Youwei
Liu, Qi
Yu, Jingyu
Zhao, Ping
Palmby, Todd R.
Goldberg, Kirsten B.
Chang, C. J. George
Patel, Paresma
Alebachew, Elleni
Tilley, Amy
Pierce, William F.
Ibrahim, Amna
Blumenthal, Gideon M.
Sridhara, Rajeshwari
Beaver, Julia A.
Pazdur, Richard
CLINICAL CANCER RESEARCH, 2018, 24 (13) : 2999 - 3004
[12] Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
Zhang, Bingnan
Long, Elisa F.
BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (03) : 775 - 779
[13] Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive H ER2-Negative Advanced Breast Cancer
Yang, Jiangping
Han, Jiaqi
Tian, Maolang
Tian, Kun
Liao, Wenjun
Yan, Xi
CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 12905 - 12913
[14] Considerations for payers in managing hormone receptor-positive advanced breast cancer
Chitre, Mona
Reimers, Kristen M.
CLINICOECONOMICS AND OUTCOMES RESEARCH, 2014, 6 : 331 - 339
[15] Changing Concepts of Hormone Receptor-Positive Advanced Breast Cancer Therapy
Chlebowski, Rowan T.
CLINICAL BREAST CANCER, 2013, 13 (03) : 159 - 166
[16] Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer
Sharvina Ziyeh
Lauren Wong
Reva K. Basho
Current Oncology Reports, 2023, 25 : 689 - 698
[17] Treating Elderly Patients With Hormone Receptor-Positive Advanced Breast Cancer
Riseberg, David
CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2015, 9 : 65 - 73
[18] Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer
Ziyeh, Sharvina
Wong, Lauren
Basho, Reva K.
CURRENT ONCOLOGY REPORTS, 2023, 25 (07) : 689 - 698
[19] Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial
Hortobagyi, Gabriel N.
BREAST CANCER RESEARCH, 2018, 20
[20] Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial
Gabriel N. Hortobagyi
Breast Cancer Research, 20

← 1 2 3 4 5 →